Navigation Links
Study looks at new bladder cancer therapy for patients unresponsive to standard treatment
Date:2/26/2008

NEW YORK (Feb. 26, 2008) -- As many as half of patients with superficial bladder cancer do not respond to the standard first-line chemotherapy placed into the bladder, according to current multi-center outcomes data. When this happens, typically, their only option is surgical removal of the bladder. Now, researchers at the Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian Hospital and Columbia University Medical Center are investigating an FDA-approved metastatic breast-cancer drug called Abraxane that may prove a safe and effective alternative to surgery for these patients.

Bladder cancer is the fourth leading cause of cancer in men and the ninth leading cause of cancer in women in the United States. In a given year, more than 60,000 new cases are diagnosed, and 13,000 will die from the disease.

"When the standard treatment does not work, currently the only option is surgical removal of the bladder -- something that, for all patients, is unappealing, and for some sicker patients is not even possible. With this study, we hope to find an effective second line medical option for these patients," says Dr. James McKiernan, director of urologic oncology at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital and Columbia University Medical Center, and vice chairman of the Department of Urology and assistant professor of urology at Columbia University College of Physicians and Surgeons.

The Phase I/II study will follow 18 patients for six weeks to assess dosage safety, followed by a second group of 19 patients who will be followed for six weeks to measure the effectiveness of the therapy.

The study is open to patients with recurrent bladder cancer that has not responded to standard therapy -- BCG (bacillus Calmette-Guerin) treatment.

In 2006, Dr. McKiernan, together with departmental chair Dr. Mitchell C Benson, led a phase I study of the drug Taxotere, also used to treat breast cancer, on a similar patient population, finding the drug to be safe with 12 of 18 patients responding (results were published in the July 1, 2006, Journal of Clinical Oncology). Since then, a favorable percentage of patients have survived with intact bladders.

Abraxane, he believes, will show similar or better results. "Abraxane has an analogous structure to Taxotere, but has the advantage of being more soluble due to its solvent-free formulation allowing for administration at higher concentrations," says Dr. McKiernan. "In one study of Abraxane for metastatic breast cancer, the drug successfully shrank tumors and had few side effects."


'/>"/>

Contact: Jennifer Homa
jeh9057@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. LSU researchers study coastal community bounce back
2. Childrens Hospital 1 of 10 pediatric hospitals in US selected to study liver disease in kids
3. Yoga Journal Releases 2008 Yoga in America Market Study
4. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
5. Study finds recent trend of growing US disparities in health not inevitable
6. LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
7. Faux Fido eases loneliness in nursing home residents as well as real dog, SLU study finds
8. Study details link between obesity, carbs and esophageal cancer
9. Interactive Patient Television Drives Patient Satisfaction, LodgeNet Healthcare Study Shows
10. Trial finds tenofovir gel safe for daily use and most women adhered to study regimens
11. Study finds spine surgery yields greater benefits over nonsurgical treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... 2017 , ... Healthful Balance announces the national release of ... by Ed Stroup, was created to offer the highest quality vitamins and supplements ... service. Healthful Balance products can be purchased online through their website, or can ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of ... will be featuring DRTV campaigns regarding the topic of Beauty and Personal Care. ... version of themselves. What better way to commit to these changes than beginning with ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development ... to infusing high speed technology into the fabric of an entire community. A ... of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this initiative ...
(Date:1/17/2017)... TX (PRWEB) , ... January 17, 2017 , ... Mirror ... have earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice ... named part of this elite group of providers. , Produced by Zeltiq, CoolSculpting ...
(Date:1/17/2017)... ... 17, 2017 , ... Peoples Health is pleased to announce ... Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more than ... to our provider network, and the addition will benefit our members in the ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 Interpace Diagnostics Group, Inc., (NASDAQ: ... diagnostic tests and pathology services for evaluating risks of ... dated January 13, 2017 from the NASDAQ Listing Qualifications ... the requirement of the NASDAQ Stock Market to maintain ... The letter noted that for the last ...
(Date:1/17/2017)... and Markets has announced the addition of the "The Top 200 ... ... profiles the leading 200 manufacturers and distributors of molecular diagnostics products worldwide. ... States and Europe to ... Profile information for each company in The Top 200 Molecular Diagnostics Companies ...
(Date:1/17/2017)... 17, 2017 Catherine ... http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ...      (Logo: ... European Neurological Review , ... Amey reports that despite standard care, temperatures ...
Breaking Medicine Technology: